Clinical, pathological and molecular prognostic factors in prostate cancer decision-making process

Pierfrancesco Bassi, Dario Pugliese, Giuseppe Palermo, Angelo Totaro, Francesco Pinto

Risultato della ricerca: Contributo in rivistaArticolo in rivista

6 Citazioni (Scopus)

Abstract

Prostate cancer is the most common urologic neoplasm and the second leading cause of cancer-related death among men in many developed countries. Given the highly heterogeneous behaviour of the disease, there is a great need for prognostic factors, in order to stratify the clinical risk and give the best treatment options to the patient. Clinical factors, such as prostate-specific antigen value and derivatives, and pathological factors, such as stage and Gleason grading, are well kown prognostic factors. Nomograms can provide useful prediction in each clinical sceario. The field of molecular biomarkers is briskly evolving towards personalized medicine. TMPRSS2-ERG fusion, deletion of PTEN ed and gene panels are some of the more extensively explored molecular features in prostate cancer outcome prediction. In the near future, circulating tumour cells, exosomes and microRNAs could give us further, not invasive important tools.
Lingua originaleEnglish
pagine (da-a)14-20-20
RivistaUrologia
Volume82
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • prostate cancer, prognostic factors

Fingerprint

Entra nei temi di ricerca di 'Clinical, pathological and molecular prognostic factors in prostate cancer decision-making process'. Insieme formano una fingerprint unica.

Cita questo